Loading
A phase 3 trial in lung cancer, run by Shanghai Pulmonary Hospital, Shanghai, China, not yet recruiting.
Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT is a phase 3, randomised interventional study registered as NCT07169903 by Shanghai Pulmonary Hospital, Shanghai, China, with a registry enrolment figure of 587 participants, started 2025-10-01 and due to reach its primary completion in 2033-03-31. Interventions recorded: Pulmonary segmentectomy. Conditions listed: Lung Adenocarcinoma. Primary outcome: Overall Survival (OS); Recurrence-Free Survival (RFS). Lung eligibility wording from the registry: "* Suspicion of non-small cell lung cancer (NSCLC)". Sites: China. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.